(MENAFNEditorial)
that forms in the tissues of the prostate a gland in the male reproductive system found below the bladder and in front of the rectum. Although prostate cancer cases have been reported in all age groups the majority of cases occur in men over the age of 65 years. Prostate cancer is the second most common cancer in men worldwide. An estimated 1.1 million men worldwide were diagnosed with prostate cancer in 2012 accounting for 15% of all the cancers diagnosed in men (IARC 2014).
This report provides an overview of the risk factors comorbidities and the global and historical trends for prostate cancer in the nine major markets (9MM) (US France Germany Italy Spain UK Japan Brazil and Canada). It includes a 10-year epidemiological forecast for the diagnosed incident cases of prostate cancer segmented by age (in 10-year age groups beginning at age 40 years and ending at age =85 years) in these markets.
In 2013 there were a total of 813462 diagnosed incident cases of prostate cancer in the 9MM. epidemiologists forecast that the diagnosed incident cases in the 9MM will increase to 1106349 cases by 2023 at an Annual Growth Rate (AGR) of 3.60%. All markets will see an increase in the number of cases with AGRs ranging from 0.71% (Germany) to 8.66% (Brazil). The 9MM had an estimated 3381581 diagnosed five-year prevalent cases of prostate cancer in 2013. The number of diagnosed five-year prevalent cases will increase over the next decade to 4618451 diagnosed prevalent cases by 2023 at an AGR of 3.66%.
Brazil appears to be a market of concern with a rapidly increasing incidence and prevalence of prostate cancer. epidemiologists calculated that Brazil will have the highest AGR in diagnosed incident cases among the 9MM (8.66%) as well as the highest AGR in five-year diagnosed prevalent cases (8.98%).
Visit Complete Report :http://www.marketresearchstore.com/report/epicast-report-prostate-cancer-epidemiology-forecast-to-18226
Scope
- The Prostate Cancer EpiCast Report provides an overview of the risk factors comorbidities and global trends for prostate cancer in the nine major markets (9MM) (US France Germany Italy Spain UK Japan Brazil and Canada). It includes a 10-year epidemiological forecast for the diagnosed incident cases of prostate cancer segmented by age (in 10-year age groups beginning at age 40 years and ending at age =85 years) and clinical stage at diagnosis in these markets. The report also provide a forecast for the diagnosed five-year prevalent cases of prostate cancer segmented by castration resistance status and bone metastases status.
- The prostate cancer epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth high quality transparent and market-driven providing expert analysis of disease trends in the 9MM.
Reasons to buy
- Develop business strategies by understanding the trends shaping and driving the global prostate cancer market.
- Quantify patient populations in the global prostate cancer market to improve product design pricing and launch plans.
- Organize sales and marketing efforts by identifying the age groups and clinical stage at diagnosis that present the best opportunities for prostate cancer therapeutics in each of the markets covered.
Get Sample Copy of Report:
Browse Full Report with TOC :
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.